Physician profile
Alyssa Miceli
NPI 1497136758
$14,087.61
in general payments reported to CMS, 2019-2025
31 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $1,300 · 2021: $379 · 2022: $2,880 · 2023: $2,687 · 2024: $3,161 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,375 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,374.72 |
| Education | $307.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,229.19 | 2019-2025 | |
| Pfizer INC. | $1,212.49 | 2020-2025 | |
| Allergan, INC. | $1,000.00 | 2020 | |
| Janssen Biotech, INC. | $832.98 | 2022-2025 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $828.23 | 2021-2025 | Adbry |
| Incyte Corporation | $810.68 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $800.42 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $569.52 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Galderma Laboratories, L.P. | $567.20 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $545.50 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $540.53 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $527.47 | 2019-2024 | Dupixent, Libtayo |
| Amgen INC. | $445.61 | 2022-2025 | Otezla, Enbrel, Otezla |
| Genzyme Corporation | $382.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $376.87 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $353.70 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $227.88 | 2023-2024 | Vtama |
| Journey Medical Corporation | $194.66 | 2022-2025 | |
| Epi Health, LLC | $138.17 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $127.28 | 2023-2024 | Sotyktu |
| Celgene Corporation | $81.06 | 2019 | |
| Verrica Pharmaceuticals INC. | $57.83 | 2023-2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.05 | 2022-2024 | Spevigo |
| Hydrofera LLC | $50.78 | 2024 | Hydrofera Blue |
| Organon LLC | $22.94 | 2025 | Vtama |
| Biofrontera INC. | $21.84 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $19.45 | 2024 | Seysara |
| Vyne Pharmaceuticals INC. | $18.13 | 2021 | |
| Fresenius Kabi USA, LLC | $17.20 | 2023 | |
| Sandoz INC. | $17.00 | 2025 | Hyrimoz |
| Mayne Pharma Commercial LLC | $15.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Miceli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.